Medopharm Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Medopharm Pharmaceutical Export Portfolio Dataset — 21 Products, $50.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Medopharm — Pharmaceutical Exporter Profile (2026) | 21 Products, $50.2M Trade | TransData Nexus

Medopharm

Indian Pharmaceutical Exporter · Antibiotics Specialist · $50.2M Total Trade · DGFT Verified

Medopharm is an Indian pharmaceutical exporter with a total trade value of $50.2M across 21 products in 10 therapeutic categories. Based on 1,293 verified export shipments from Indian Customs (DGFT) records, Medopharm is the #1 Indian exporter in 3 products including Metronidazole, Erythromycin, Glibenclamide. Top exports include Amoxicillin ($7.3M), Metronidazole ($7.0M), Paracetamol ($6.1M).

Medopharm — Export Portfolio & Destination Treemap

Medopharm pharmaceutical export portfolio — 21 products across 10 therapeutic categories. Source: Indian Customs (DGFT).

Who is Medopharm? — Company Overview & Market Position

Medopharm Private Limited, established in 1970 by the late Shri Mohanmulji Chordia, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of affordable medicines. Headquartered in Chennai, Tamil Nadu, India, Medopharm has expanded its operations over five decades to become a significant player in the global pharmaceutical industry. The company is privately held and is part of the Chordia Group, which encompasses diverse industries such as pharmaceuticals, packaging, food, and distribution, with an estimated valuation of USD 320 million.

As of February 28, 2025, Medopharm employed approximately 462 individuals. The company's product portfolio includes over 300 pharmaceutical products across various therapeutic areas, including antibiotics, cardiology, central nervous system (CNS) disorders, and anti-diabetics. Medopharm exports its products to more than 100 countries, reflecting its extensive global reach.

What Does Medopharm Export? — Product Portfolio Analysis

Top Products by Export Value

1Amoxicillin$7.3M 2

Product Portfolio — Top 21 by Export Value

Medopharm exports 21 pharmaceutical products across 10 therapeutic categories. Market leader (#1 exporter) in 3 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Amoxicillin	Antibiotics	$7.3M	147	1.2%	6
2	Metronidazole	Advanced Antibiotics	$7.0M	141	3.5%	1
3	Paracetamol	Analgesics & Antipyretics	$6.1M	180	1.7%	13
4	Albendazole	Antimalarial & Antiparasitic	$5.3M	108	7.3%	2
5	Ciprofloxacin	Antibiotics	$4.5M	91	1.5%	7
6	Potassium	Nutritional Supplements	$3.4M	68	0.5%	13
7	Ofloxacin	Advanced Antibiotics	$3.1M	62	1.0%	8
8	Erythromycin	Antibiotics	$3.0M	61	3.8%	1
9	Azithromycin	Antibiotics	$2.3M	103	1.2%	15
10	Griseofulvin	Advanced Antifungals	$1.5M	34	4.2%	2
11	Doxycycline	Antibiotics	$1.2M	48	1.0%	13
12	Fluoxetine	CNS & Psychiatric	$1.1M	21	0.4%	13
13	Enalapril	Cardiovascular	$1.0M	84	0.4%	13
14	Pyrimethamine	Antimalarial & Antiparasitic	$700.0K	14	1.5%	5
15	Loperamide	Gastrointestinal	$643.7K	15	0.9%	15
16	Sulfadoxine	Antimalarial & Antiparasitic	$600.0K	12	1.1%	5
17	Glibenclamide	Advanced Diabetes Medications	$420.3K	48	1.0%	1
18	Chloroquine	Antimalarial & Antiparasitic	$269.4K	9	0.2%	13
19	Quinine	Antimalarial & Antiparasitic	$231.6K	7	1.2%	12
20	Mebendazole	Antimalarial & Antiparasitic	$220.3K	34	1.6%	10
21	Praziquantel	Antimalarial & Antiparasitic	$97.8K	6	3.3%	6

Medopharm exports 21 pharmaceutical products across 10 therapeutic categories with a total export value of $50.2M. The company is the #1 Indian exporter in 3 products: Metronidazole, Erythromycin, Glibenclamide. The top category is Antibiotics (36.8% of portfolio), followed by Advanced Antibiotics (20.2%), indicating a concentrated portfolio with the top 5 products accounting for 60.5% of total export value.

Medopharm — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Medopharm operates four manufacturing facilities: three in India and one in Sudan. In India, the facilities are located in Chennai, Tamil Nadu, and Malur, Karnataka. The Chennai facility is approved by multiple regulatory bodies, including the UK Medicines and Healthcare products Regulatory Agency (MHRA), cGMP, and the Ministry of Health of various countries. The Malur facility is also approved by the Ministry of Health of several countries.

The manufacturing units are equipped with state-of-the-art infrastructure to produce a diverse range of pharmaceutical products, including tablets, capsules, dry syrups, and oral suspensions. Medopharm is recognized as the only company in India utilizing aqueous coating technology on tablets, highlighting its commitment to innovation in pharmaceutical manufacturing.

3Key Leadership

Medopharm is led by a team of experienced professionals committed to the company's mission of providing affordable and high-quality medicines globally. The leadership team includes:

Ranjitmal Chordia: Chairman
Sampath Mal Chordia: Founding Partner
Sanjay Dasmohapatra: Chief Operating Officer

These leaders, along with other key executives, drive Medopharm's strategic direction and operational excellence.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Medopharm Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Medopharm has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities are approved by various regulatory agencies, such as the UK MHRA and the Ministry of Health in multiple countries, ensuring compliance with international standards.

In the United States, Medopharm's products are subject to the Food and Drug Administration (FDA) regulations. While specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, Medopharm's adherence to global quality standards suggests a commitment to meeting regulatory requirements in these markets.

In the European Union, Medopharm's products are manufactured in compliance with Good Manufacturing Practice (GMP) standards, as evidenced by approvals from the UK MHRA and other European regulatory bodies. This compliance facilitates market access within the EU.

2Emerging Markets

Medopharm has strategically expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facilities are approved by various regulatory agencies in countries such as Uganda, Tanzania, Nigeria, Zimbabwe, Malawi, Ethiopia, Ghana, Kenya, Congo, Ivory Coast, and by delegations from the Ministry of Health and WHO cGMP.

Medopharm — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Medopharm's FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available. However, the company's adherence to international quality standards, including approvals from the UK MHRA and other regulatory bodies, indicates a commitment to meeting global regulatory requirements. Medopharm's focus on quality assurance and compliance suggests that it is well-positioned to navigate the regulatory landscape in the United States.

2WHO & EU GMP

Medopharm's manufacturing facilities are approved by various regulatory agencies, including the UK MHRA and the Ministry of Health in multiple countries, ensuring compliance with international standards. The company's commitment to quality is further demonstrated by its adherence to WHO cGMP guidelines, as evidenced by approvals from the Ministry of Health and WHO cGMP in countries such as Uganda, Tanzania, Nigeria, Zimbabwe, Malawi, Ethiopia, Ghana, Kenya, Congo, Ivory Coast, and by delegations from the Ministry of Health and WHO cGMP.

3CDSCO & Indian Regulatory

Medopharm — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Medopharm operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. While specific market share data is not publicly available, Medopharm's extensive product portfolio, global presence, and commitment to quality position it as a significant player in the market. The company's focus on affordable medicines and strategic partnerships further enhance its competitive edge.

2Key Differentiators

Medopharm's key differentiators include its extensive experience of over five decades in pharmaceutical manufacturing, a diverse product portfolio across various therapeutic areas, and a strong commitment to quality assurance. The company's unique use of aqueous coating technology on tablets and its adherence to international quality standards set it apart in the industry.

3Strategic Position

Medopharm's current strategic direction focuses on expanding its global footprint through the establishment of additional manufacturing units both domestically and internationally. The company's emphasis on contract manufacturing and branded generics aligns with its goal to be a trusted partner for global pharmaceutical companies. Future outlooks include further diversification of its product portfolio and strengthening its presence in emerging markets.

Buyer Due Diligence Brief — Evaluating Medopharm as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Medopharm has a significant track record in pharmaceutical manufacturing, with over 300 products in its portfolio and exports to more than 100 countries. The company's manufacturing facilities are approved by various regulatory agencies, including the UK MHRA and the Ministry of Health in multiple countries, ensuring compliance with international standards. Medopharm's commitment to quality assurance and environmental protection further underscores its reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Medopharm as a supplier:

FDA Approval: To ensure compliance with U.S. regulations, verify FDA facility registrations and approved ANDAs.
WHO-GMP Certification: Confirm adherence to World Health Organization Good Manufacturing Practice standards.
EU GMP Certification: Ensure compliance with European Union Good Manufacturing Practice standards.

Frequently Asked Questions — Medopharm

How many pharmaceutical products does Medopharm export from India?

Medopharm exports 21 pharmaceutical products across 10 therapeutic categories. The top exports are Amoxicillin ($7.3M), Metronidazole ($7.0M), Paracetamol ($6.1M), Albendazole ($5.3M), Ciprofloxacin ($4.5M). Total export value is $50.2M.

What is Medopharm's total pharmaceutical export value?

Medopharm's total pharmaceutical export value is $50.2M, based on 1,293 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Medopharm the #1 Indian exporter?

Medopharm is the #1 Indian exporter in 3 products: Metronidazole (3.5% market share), Erythromycin (3.8% market share), Glibenclamide (1.0% market share).

What therapeutic categories does Medopharm cover?

Medopharm exports across 10 therapeutic categories. The largest are Antibiotics (36.8%, 5 products), Advanced Antibiotics (20.2%, 2 products), Antimalarial & Antiparasitic (14.8%, 7 products).

Get Full Medopharm Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.